Indication · Laboratory Medicine & Pathology
Cancer detection and genomic testing
Last checked: Nov 20, 2026Source: FDA, ClinicalTrials.gov
Devices
590
Cleared or approved since 2000
PMA and De Novo
97
Higher-risk or first-of-kind devices
Breakthrough devices
9
Authorized through June 30, 2026
Recruiting device trials
56
274 device trials in all
Breakthrough-designated devices
- Guardant360 CDxGuardant Health, Inc. · 2026
- FoundationOne CDxFoundation Medicine, Inc. · 2026
- Koios DS (3.8)Koios Medical, Inc. · 2026
6 more devices with a free account
Devices
590 devices. PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.
- FoundationOne CDx
Foundation Medicine, Inc. · PMA · Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System · newest 2026 · 41 decisions
- PD-L1 IHC 22C3 pharmDx
Agilent Technologies, Inc. · PMA · Immunohistochemistry Assay, Antibody, Programmed Death-Ligand 1 · newest 2026 · 20 decisions
- FoundationOne Liquid CDx
Foundation Medicine, Inc. · PMA · Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System · newest 2026 · 18 decisions
57 more devices with a free account
Showing the first 60. Narrow by pathway, or open a device type below.
Device trials
Device studies on ClinicalTrials.gov for this condition, any status, newest update first.
- The DISCOVER StudyActive, not recruiting
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT07390643 · 100 participants (planned) · Start Feb 11, 2026 · Primary completion Sep 24, 2026
Device: GRAIL Galleri MCED test · For: Cancer; Cancer Diagnosis
Sites: Boston, Massachusetts
- Triton 1.5 Robotic System for Diagnostic Colonoscopy in the Middle EastActive, not recruiting
Neptune MedicalNot on our public-company list
NCT07835542 · 30 participants (planned) · Start Oct 13, 2026 · Primary completion Nov 30, 2026
Device: Diagnostic Test: Diagnostic Colonoscopy · For: Colonoscopy; Colorectal Cancer Screening
Sites: Abu Dhabi, United Arab Emirates
- The Vanguard Study: Testing a New Way to Screen for CancerPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT06995898 · 24,000 participants (planned) · Start Jun 18, 2025 · Primary completion Jan 31, 2029
Device: Device Usage · For: Bladder Carcinoma; Breast Carcinoma; Colorectal Carcinoma and 8 more
Sites: Pleasanton, California; San Diego, California; Cheyenne Wells, Colorado · 49 sites in all
271 more trials with a free account
Device types
FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.
- Instrument, Biopsy (KNW)183
- Biopsy Needle (FCG)60
- Radiological Computer-Assisted Prioritization Software For Lesions (QFM)36
- Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer (QDQ)23
- Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP)19
- Somatic Gene Mutation Detection System (OWD)18
- Computer-Assisted Diagnostic Software For Lesions Suspicious For Cancer (POK)16
- System, Test, Immunological, Antigen, Tumor (MOI)15
- Test, Epithelial Ovarian Tumor-Associated Antigen (Ca125) (LTK)14
- Kappa, Antigen, Antiserum, Control (DFH)13
- System, Test, Carbohydrate Antigen (Ca19-9), For Monitoring And Management Of Pancreatic Cancer (NIG)12
- Kit, Test,Alpha-Fetoprotein For Testicular Cancer (LOJ)11
- Lambda, Antigen, Antiserum, Control (DEH)9
- System, Laser, Photodynamic Therapy (MVF)9
- Microscope, Automated, Image Analysis, Operator Intervention (NOT)9
- System, Test, Carcinoembryonic Antigen (DHX)8
- System, Immunomagnetic, Circulating Cancer Cell, Enumeration (NQI)8
- System, Automated Scanning Microscope And Image Analysis For Fluorescence In Situ Hybridization (Fish) Assays (NTH)8
- Next Generation Sequencing Based Tumor Profiling Test (PZM)8
- Microscope, Automated, Image Analysis, Immunohistochemistry,Operator Intervention,Nuclear Intensity & Percent Positivity (NQN)7
- Ovarian Adnexal Mass Assessment Score Test System (ONX)6
- Bcr/Abl1 Monitoring Test (OYX)6
- Immunohistochemistry Antibody Assay, C-Kit (NKF)5
- Automated Digital Image Manual Interpretation Microscope (OEO)5
- Test, Epithelial Ovarian Tumor Associated Antigen (He4) (OIU)5
- Immunohistochemistry Assay, Antibody, Programmed Death-Ligand 1 (PLS)5
- Lynch Syndrome Test System (PZJ)5
- Probe, Uptake, Nuclear (IZD)4
- Cancer Predisposition Risk Assessment System (QAZ)4
- Software, Similarity Score Algorithm, Tissue Of Origin For Malignant Tumor Types (OIW)3
Research
- Device studies on cancer screening across PubMed, Europe PMC and OpenAlex
- PubMed ↗
- Google Scholar ↗
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.